SCHEMBL29378232

SCHEMBL29378232

Fc1ccccc1N1CCN(Cc2ccc(CCl)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.65
ALDH1A1 P00352 5/20 0.65
POLB P06746 1/20 0.65
TSHR P16473 1/20 0.65
HSD17B10 Q99714 2/20 0.63
TDP1 Q9NUW8 3/20 0.62
DRD4 P21917 4/20 0.57
DRD3 P35462 3/20 0.57
DRD2 P14416 2/20 0.56
GAA P10253 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPK1 P28482 1/20 0.56
LMNA P02545 1/20 0.56
ADRA1D P25100 1/20 0.54
ADRA1A P35348 1/20 0.54
ADRA1B P35368 1/20 0.54
CACNA1G O43497 1/20 0.54
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22533031 1.00 KDM4E (0.65) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL13568797 0.89 ALDH1A1 (0.71) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL25672951 0.86 KDM4E (0.63) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL22532815 0.82 ADRA1B (0.54) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL8744970 0.81 CACNA1G (0.57) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL22533043 0.81 GRM2 (0.54) KDM4EALDH1A1POLBTSHRHSD17B10
Hydrochloric Acid SCHEMBL8745014 0.80 CACNA1G (0.56) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL11556492 0.80 LMNA (0.59) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL6751057 0.79 KDM4E (0.61) KDM4EALDH1A1POLBTSHRHSD17B10
SCHEMBL23102077 0.78 KDM4E (0.59) KDM4EALDH1A1POLBTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192450-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS C4 Therapeutics, Inc. (US) 2023-06-14 EP disclosed
CN-116194438-A Advantageous treatment of Ikaros or Aiolos mediated disorders C4医药公司 2023-05-30 CN disclosed
WO-2022032132-A1 ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS C4 THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed